CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $3.16M, lower than 95% of all stocks globally
- PositionOperating margin is -5481%, lower than 95% of its Biotechnology peers (median -38%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
290.83MUSDvs all stocks (USD)
Revenue (TTM)
3.16MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
-69.38%vs all stocks
Market Capitalization
290.83MUSDvs all stocks (USD)
Enterprise Value
33.22MUSDvs all stocks (USD)
Forward P/E
-1.91xvs Biotechnology peers
Price to Sales (TTM)
92.96xvs Biotechnology peers
Price to Book (MRQ)
1.08xvs Biotechnology peers
Enterprise to Revenue
10.52xvs Biotechnology peers
Enterprise to EBITDA
-0.1960xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-30.28%vs Biotechnology peers
Return on Equity (TTM)
-46.05%vs Biotechnology peers
Revenue (TTM)
3.16MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0580USDUpdated Sep 28, 2026Quarterly Revenue Growth
-17.50%vs Biotechnology peers
Gross Profit (TTM)
3.16MUSDvs all stocks (USD)
EBITDA (TTM)
-169.78MUSDvs all stocks (USD)
Net Income (TTM)
-156.50MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-17.50%vs Biotechnology peers
Operating Cash Flow (TTM)
-136.34MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-86.62MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.85MUSDFY2025 · Dec 31, 2025Operating Income
-160.36MUSDvs all stocks (USD)
Pre-tax Income
-143.44MUSDFY2025 · Dec 31, 2025Net Income
-143.44MUSDFY2025 · Dec 31, 2025EBIT
-160.36MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-160.17MUSDFY2025 · Dec 31, 2025Research & Development
136.81MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
26.41MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.93MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.66USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.66USDFY2025 · Dec 31, 2025Basic Shares Outstanding
53.85MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
53.85MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-143.44MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-134.26MUSDFY2025 · Dec 31, 2025Free Cash Flow
-134.43MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
101.77MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-143.44MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
188.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.33MUSDFY2025 · Dec 31, 2025Other Non-cash Items
561.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-55.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.28MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-565.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-165.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-385.88MUSDFY2025 · Dec 31, 2025Sale of Investments
292.56MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-93.48MUSDFY2025 · Dec 31, 2025Other Financing Charges
-34.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-34.00KUSDFY2025 · Dec 31, 2025Shares Outstanding
54.77MSharesUpdated Sep 28, 2026Float Shares
42.81MSharesUpdated Sep 28, 2026Shares Short
4.49MSharesUpdated Sep 28, 2026Short Ratio
7.39daysvs all stocks
Short % of Shares Outstanding
12.60%vs all stocks
% Held by Insiders
14.78%vs all stocks
% Held by Institutions
92.45%vs all stocks
Total Cash (MRQ)
261.31MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.77USDUpdated Sep 28, 2026Total Debt (MRQ)
954.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0035xvs Biotechnology peers
Current Ratio (MRQ)
27.99xvs Biotechnology peers
Book Value per Share (MRQ)
4.95USDUpdated Sep 28, 2026Total Assets
353.77MUSDvs all stocks (USD)
Total Current Assets
351.80MUSDFY2025 · Dec 31, 2025Total Liabilities
14.00MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.98MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
549.00KUSDFY2025 · Dec 31, 2025Total Current Liabilities
13.45MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
101.58MUSDFY2025 · Dec 31, 2025Other Short-term Investments
239.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
668.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.73MUSDFY2025 · Dec 31, 2025Short-term Debt
720.00KUSDFY2025 · Dec 31, 2025Long-term Debt
549.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
54.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-334.22MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
339.77MUSDvs all stocks (USD)
52-Week Low
4.99USDUpdated Sep 28, 202652-Week High
33.68USDUpdated Sep 28, 202652-Week Change
-69.38%vs all stocks
50-Day MA
6.42USDUpdated Sep 28, 2026200-Day MA
12.39USDUpdated Sep 28, 2026Avg 10-Day Volume
521.76KSharesUpdated Sep 28, 2026Avg 30-Day Volume
591.62KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-2.88USDUpdated Sep 28, 2026Other Income / Expense
-15.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -5481%, lower than 95% of its Biotechnology peers (median -38%)Significant
Operating margin: -54.81Industry median: -0.38Industry P5: -43.63Peers compared: 260
Current ratio is 27.99×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 27.99Industry median: 5.71Industry P95: 22.21Peers compared: 260
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.07×)Notable
Debt-to-equity: 0.00Industry median: 0.07Industry P5: 0.00Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $3.16M, lower than 95% of all stocks globallySignificant
Revenue (USD): 3,158,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cutia Therapeutics Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inventage Lab Inc.
Tier 1ProductionApproval-Gated PipelineRule
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Dirui Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Fulcrum Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
X4 Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Hunan Kylinsec Technology Co., Ltd.
2 interpretationsLow-Leverage Liquidity ConfigurationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
2 interpretationsLow-Leverage Liquidity ConfigurationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Aduro Clean Technologies Inc.
2 interpretationsLow-Leverage Liquidity ConfigurationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC